Alimera Sciences Inc (NASDAQ:ALIM)
| 2.62 Delayed Data As of 1:18pm ET |  -0.02 / -0.76%Today’s Change | 2.03 Today|||52-Week Range 7.92 | -3.51% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $18.9M |
Company Description
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
Contact Information
Alimera Sciences, Inc. 6310 Town Square Alpharetta Georgia 30005 |
Employees
Shareholders
| Mutual fund holders | 4.56% |
| Other institutional | 25.83% |
| Individual stakeholders | 15.61% |
Top Executives
| Richard S. Eiswirth | President, Chief Executive Officer & Director |
| Philip John Ashman | COO & SVP-Commercial Operations Europe |
| Russell L. Skibsted | Chief Financial Officer & Senior Vice President |
| Christopher S. Visick | Secretary, Vice President & General Counsel |
| David Dyer | Chief Retina Specialist |
